Posted by Michael Wonder on 10 Apr 2024
FDA accepts filing of new drug application for nalmefene auto-injector for the treatment of known or suspected opioid overdose
8 April 2024 - Purdue Pharma announced today that FDA has accepted for filing the company’s new drug application for the auto-injector delivery form of nalmefene hydrochloride injection.
If the auto-injector is approved, it would be the second nalmefene-containing medicine developed by Purdue to specifically address the growing number of opioid overdose deaths, including those due to fentanyl and other synthetic opioids. It would be the first nalmefene medicine available as an auto-injector.
